ABPO Abpro Holdings, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1893219 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY119.1%
TTM EPS YoY108.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR-26.1%
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA46.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets156.9%
Debt / equity—
Current ratio0.62x
Interest coverage-22.07x
Cash quality & payout
Operating cash flow / net income-3.00x
Accruals ratio184.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $9,000 | $13,000 | $108,000 | $243,000 | $313,000 | $325,000 | $514,000 | $642,000 |
| SG&A expense | $1.17M | $920,000 | $1.79M | $1.09M | $1.95M | $2.63M | $2.26M | $1.47M |
| Operating income | -$1.18M | -$933,000 | -$1.90M | -$1.34M | -$2.26M | -$2.96M | -$7.99M | -$1.93M |
| Interest expense | $2,000 | $23,000 | $24,000 | $193,000 | $174,000 | $737,000 | $81,000 | $164,000 |
| Pretax income | — | — | — | — | — | — | -$5.57M | -$307,446 |
| Income tax | — | — | — | — | — | — | — | $27,654 |
| Net income | -$940,000 | -$1.03M | $5.64M | -$1.66M | -$2.98M | -$3.89M | -$3.33M | -$335,100 |
| EBITDA | -$1.17M | -$930,000 | -$1.89M | -$1.33M | -$2.26M | -$2.95M | -$7.99M | -$1.92M |
| EPS (basic) | -0.16 | -0.23 | — | -0.63 | -1.56 | -2.29 | — | -3.27 |
| EPS (diluted) | -0.16 | -0.23 | — | -0.63 | -1.56 | -2.29 | — | -3.27 |
| Weighted avg. shares (diluted) | 5.90M | 4.49M | — | 2.61M | 1.92M | 1.70M | — | 640,606 |
| Balance sheet | ||||||||
| Cash & equivalents | $4.24M | $5.41M | $82,000 | $343,000 | $2.03M | $1.41M | $2.99M | $141,000 |
| Receivables | — | $183,000 | $183,000 | $271,000 | $342,000 | $331,000 | $183,000 | — |
| Current assets | $5.08M | $6.70M | $896,000 | $1.23M | $3.07M | $2.22M | $3.78M | $1.56M |
| PP&E, net | — | — | — | — | $27,000 | $31,000 | $37,000 | — |
| Total assets | $5.24M | $6.87M | $1.06M | $1.70M | $3.48M | $2.80M | $4.66M | $7.86M |
| Current liabilities | $8.22M | $9.12M | $9.35M | $17.30M | $20.43M | $20.61M | $19.61M | $9.04M |
| Total liabilities | $8.22M | $9.12M | $9.35M | $17.30M | $20.43M | $20.61M | $19.61M | $18.58M |
| Shareholders' equity | -$3.53M | -$2.80M | -$8.83M | -$16.14M | -$17.50M | -$18.36M | -$15.49M | -$17.81M |
| Shares outstanding | 5.90M | 5.90M | 2.73M | 2.67M | 66.40M | 50.98M | 1.69M | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.05M | -$2.08M | -$620,000 | -$2.28M | -$1.05M | -$1.50M | -$8.25M | -$997,000 |
| Investing cash flow | — | — | — | — | — | — | — | -$20,000 |
| Financing cash flow | -$123,000 | $7.41M | $359,000 | $569,000 | $1.67M | -$84,000 | $40.27M | $936,000 |
| Depreciation & amortization | $2,000 | $3,000 | $3,000 | $4,000 | $3,000 | $8,000 | $7,000 | $8,000 |
| Stock-based compensation | $208,000 | $302,000 | $331,000 | $286,000 | $360,000 | $512,000 | $396,000 | $415,000 |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.